Patient Characteristics and Disease Factors Guide the Use of Dostarlimab in Recurrent Endometrial Cancer: With Dana M. Chase, MD

In our exclusive interview, Dr Chase discussed the management of recurrent endometrial cancer, emphasizing the importance of biomarker profiles and previous therapies. For first recurrences, she explained that carboplatin and paclitaxel with pembrolizumab (Keytruda) or dostarlimab-gxly (Jemperli) is recommended for patients with mismatch repair–deficient (dMMR) disease, whereas those with MMR-proficient (pMMR) disease may benefit from carboplatin, paclitaxel, and pembrolizumab (Keytruda) or lenvatinib (Lenvima). She also highlighted findings from the phase 3 RUBY trial (NCT03981796) that supported the FDA approval of dostarlimab, showing significant improvements in progression-free and overall survival in both dMMR and pMMR patients. Chase also noted the rising incidence of endometrial cancer, its deadly nature, and the importance of clinical trials for advancing treatment options.